Authors :
Kanwar Bhanu; Sharma Shruti; Thakur Daaman; Sood Anuradha
Volume/Issue :
Volume 8 - 2023, Issue 7 - July
Google Scholar :
https://bit.ly/3TmGbDi
Scribd :
https://tinyurl.com/trujtwsm
DOI :
https://doi.org/10.5281/zenodo.8211430
Abstract :
Background : Mixed infection is a challenge
to the treating clinician. Vial hepatitis and leptospirosis
co-infection has not been frequently referred to in
medical literature as both present as acute febrile illness
with jaundice and may reveal non-specific laboratory
findings. Hepatitis A infection and leptospirosis are
prevalent in developing countries
Objective: This retrospective study is aimed at
determining the presence of hepatitis and leptospirosis
co-infection among patients of acute febrile illness with
jaundice.
Methods: Retrospective data of IgM ELISA for
leptospirosis, anti-HAV antibodies and anti-HEV
antibodies ELISA was retrieved for analysis. Serum
samples of patients of acute febrile illness with jaundice
were collected and processed. A total of 92 serum
samples were received over a period of one year from
April 2022 to March 2023 for IgM ELISA for
leptospirosis, anti-HAV antibodies and anti-HEV
antibodies ELISA.
Keywords :
HAV, HEV, ELISA, AST, ALT, MOF, ARDS.
Background : Mixed infection is a challenge
to the treating clinician. Vial hepatitis and leptospirosis
co-infection has not been frequently referred to in
medical literature as both present as acute febrile illness
with jaundice and may reveal non-specific laboratory
findings. Hepatitis A infection and leptospirosis are
prevalent in developing countries
Objective: This retrospective study is aimed at
determining the presence of hepatitis and leptospirosis
co-infection among patients of acute febrile illness with
jaundice.
Methods: Retrospective data of IgM ELISA for
leptospirosis, anti-HAV antibodies and anti-HEV
antibodies ELISA was retrieved for analysis. Serum
samples of patients of acute febrile illness with jaundice
were collected and processed. A total of 92 serum
samples were received over a period of one year from
April 2022 to March 2023 for IgM ELISA for
leptospirosis, anti-HAV antibodies and anti-HEV
antibodies ELISA.
Keywords :
HAV, HEV, ELISA, AST, ALT, MOF, ARDS.